Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
October 28, 2015 1:47 PM EDTMaxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
Gilead Sciences (GILD) Bullish Stance Reiterated at Oppenheimer Amid 'Beat and Raise' Qtr
October 28, 2015 6:25 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q3.
Lam commented, "GILD reported a healthy 3Q15 beat, with revenue and non-GAAP EPS of $8.30B and $3.22 topping Street consensus estimates of $7.81B and $2.87; GILD... More
Gilead (GILD) Slips Despite Strong Q3 Results
October 27, 2015 4:13 PM EDTGilead (NASDAQ: GILD) reported third quarter financial results today after the market close and the stock is trading down by 1.8% in the aftermarket. Revenue of $8.7 billion beat expectations of $7.8 billion. EPS of $3.22 beat consensus of $2.83.
Breaking down the numbers by therapy, HCV... More
Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
October 27, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.82 billion.
Product Sales
Total product sales for the third quarter of 2015 were $8.2 billion compared to $6.0... More
